{"id":"NCT00265330","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","officialTitle":"26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2005-12-14","resultsPosted":"2009-04-03","lastUpdate":"2021-03-25"},"enrollment":169,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Ziprasidone oral capsules","otherNames":[]}],"arms":[{"label":"Open","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed)","primaryOutcome":{"measure":"Young Mania Rating Scale (YMRS) Total Score Change From Baseline","timeFrame":"baseline and 26 Weeks; 26 Weeks Last Observation Carried Forward (LOCF)","effectByArm":[{"arm":"Ziprasidone","deltaMin":-3.8,"sd":9}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":41,"countries":["United States"]},"refs":{"pmids":["24111980"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281133&StudyName=Safety%20and%20tolerability%20of%20ziprasidone%20in%20children%20and%20adolescents%20with%20bipolar%20I%20disorder%20%28manic%20or%20mixed%29"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":162},"commonTop":["Sedation","Somnolence","Headache","Insomnia","Abdominal pain upper"]}}